HR Positive HER Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly and Company, Laekna Limited, Sermonix

The HR Positive HER Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“HR Positive HER Negative Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HR Positive HER Negative Breast Cancer Market.

Some of the key takeaways from the HR Positive HER Negative Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel HR Positive HER Negative Breast Cancer treatment therapies with a considerable amount of success over the years. 
• HR Positive HER Negative Breast Cancer companies working in the treatment market are Seagen Inc., Regor Pharmaceuticals, Verastem Oncology, Olema Pharmaceuticals, Inc, Tyme, Inc., EOC Pharma, CytomX Therapeutics, Daiichi Sankyo, Inc., AstraZeneca, Chia Tai Tianqing Pharmaceutical Group, and others, are developing therapies for the HR Positive HER Negative Breast Cancer treatment 

• Emerging HR Positive HER Negative Breast Cancer therapies in the different phases of clinical trials are- SGN-B7H4V, RGT-419B, Abemaciclib + VS-6766 + Fulvestrant, OP-1250, SM-88, EOC202, CX-2009, Dato-DXd, Camizestrant + Palbociclib, TQB3616, and others are expected to have a significant impact on the HR Positive HER Negative Breast Cancer market in the coming years.   
• In September 2023, The initial positive outcomes from the TROPION-Breast01 Phase III trial indicated that datopotamab deruxtecan (Dato-DXd) showed a statistically notable and clinically meaningful improvement in the primary metric of progression-free survival (PFS) compared to the investigator-selected chemotherapy. These results were evident among patients managing inoperable or metastatic hormone receptor (HR)-positive, HER2-low, or negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer, previously treated with endocrine-based therapy and at least one systemic therapy.
• In January 2023, Context Therapeutics Inc., a company dedicated to pioneering innovative therapies for solid tumors, particularly focusing on female-related cancers, announced that its clinical trial partner, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), obtained FDA approval for ORSERDU (elacestrant). This approval targets the treatment of postmenopausal women or adult men dealing with estrogen receptor–positive (ER+), HER2-negative (HER2-), and Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer. ORSERDU is intended for individuals experiencing disease progression following at least one line of endocrine therapy.
• On January 27, 2023, The FDA has granted approval for elacestrant (Orserdu) to treat individuals with advanced or metastatic breast cancer who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated conditions. This approval is specifically for those patients who have experienced disease progression after undergoing at least one round of endocrine therapy.
• In January 2023, ENHERTU® (trastuzumab deruxtecan) by Daiichi Sankyo and AstraZeneca has received approval in the European Union (EU) as a standalone therapy. It is intended for adult patients dealing with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. These patients should have undergone previous chemotherapy in the metastatic setting or experienced disease recurrence either during or within six months after completing adjuvant chemotherapy.
• In February 2023, Gilead Sciences’ Trodelvy, newly approved by the FDA, has made a significant entry into the breast cancer arena, which is pivotal for the drug’s commercial success and the broader oncology aspirations of the company. Gilead announced the FDA approval of Trodelvy for previously treated HR-positive, HER2-negative breast cancer. Patients eligible for this therapy must have undergone endocrine therapy and received at least two additional therapies in the metastatic setting. Trodelvy had previously obtained approval for treating triple-negative breast cancer. However, the HR-positive, HER2-negative disease encompasses a considerably larger patient group, constituting approximately two-thirds of all breast cancer cases.

HR Positive HER Negative Breast Cancer Overview

If the cells in a breast cancer have estrogen and progesterone receptors, the cancer cells may be receiving signals from these hormones that encourage cell proliferation. This is known as an HR-positive diagnosis. Additionally, HER-2 proteins, or receptors, which aid in regulating the growth and repair of breast cells, are examined in cancer tissue. Because HER-2-negative breast cancers have cells with little to no HER-2 protein, they grow more slowly and generally have a better prognosis than HER-2-positive cancers.

Get a Free Sample PDF Report to know more about HR Positive HER Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-pipeline-insight

Emerging HR Positive HER Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• SGN-B7H4V: Seagen Inc.
• RGT-419B: Regor Pharmaceuticals
• Abemaciclib + VS-6766 + Fulvestrant: Verastem Oncology
• OP-1250: Olema Pharmaceuticals, Inc
• SM-88: Tyme, Inc.
• EOC202: EOC Pharma
• CX-2009: CytomX Therapeutics
• Dato-DXd: Daiichi Sankyo, Inc.
• Camizestrant + Palbociclib: AstraZeneca
• TQB3616: Chia Tai Tianqing Pharmaceutical Group

HR Positive HER Negative Breast Cancer Route of Administration

HR Positive HER Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HR Positive HER Negative Breast Cancer Molecule Type

HR Positive HER Negative Breast Cancer Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

HR Positive HER Negative Breast Cancer Pipeline Therapeutics Assessment

• HR Positive HER Negative Breast Cancer Assessment by Product Type
• HR Positive HER Negative Breast Cancer By Stage and Product Type
• HR Positive HER Negative Breast Cancer Assessment by Route of Administration
• HR Positive HER Negative Breast Cancer By Stage and Route of Administration
• HR Positive HER Negative Breast Cancer Assessment by Molecule Type
• HR Positive HER Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s HR Positive HER Negative Breast Cancer Report covers around 53+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further HR Positive HER Negative Breast Cancer product details are provided in the report. Download the HR Positive HER Negative Breast Cancer pipeline report to learn more about the emerging HR Positive HER Negative Breast Cancer therapies

Some of the key companies in the HR Positive HER Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for HR Positive HER Negative Breast Cancer are – Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., and others.

HR Positive HER Negative Breast Cancer Pipeline Analysis:

The HR Positive HER Negative Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of HR Positive HER Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HR Positive HER Negative Breast Cancer Treatment.
• HR Positive HER Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HR Positive HER Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HR Positive HER Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about HR Positive HER Negative Breast Cancer drugs and therapies

HR Positive HER Negative Breast Cancer Pipeline Market Drivers

• Rising incidence of Breast Cancer, increase in Research and Development activities are some of the important factors that are fueling the HR Positive HER Negative Breast Cancer Market.

HR Positive HER Negative Breast Cancer Pipeline Market Barriers

• However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the HR Positive HER Negative Breast Cancer Market growth.

Scope of HR Positive HER Negative Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key HR Positive HER Negative Breast Cancer Companies: Seagen Inc., Regor Pharmaceuticals, Verastem Oncology, Olema Pharmaceuticals, Inc, Tyme, Inc., EOC Pharma, CytomX Therapeutics, Daiichi Sankyo, Inc., AstraZeneca, Chia Tai Tianqing Pharmaceutical Group, and others
• Key HR Positive HER Negative Breast Cancer Therapies: SGN-B7H4V, RGT-419B, Abemaciclib + VS-6766 + Fulvestrant, OP-1250, SM-88, EOC202, CX-2009, Dato-DXd, Camizestrant + Palbociclib, TQB3616, and others
• HR Positive HER Negative Breast Cancer Therapeutic Assessment: HR Positive HER Negative Breast Cancer current marketed and HR Positive HER Negative Breast Cancer emerging therapies
• HR Positive HER Negative Breast Cancer Market Dynamics: HR Positive HER Negative Breast Cancer market drivers and HR Positive HER Negative Breast Cancer market barriers 

Request for Sample PDF Report for HR Positive HER Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. HR Positive HER Negative Breast Cancer Report Introduction

2. HR Positive HER Negative Breast Cancer Executive Summary

3. HR Positive HER Negative Breast Cancer Overview

4. HR Positive HER Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. HR Positive HER Negative Breast Cancer Pipeline Therapeutics

6. HR Positive HER Negative Breast Cancer Late Stage Products (Phase II/III)

7. HR Positive HER Negative Breast Cancer Mid Stage Products (Phase II)

8. HR Positive HER Negative Breast Cancer Early Stage Products (Phase I)

9. HR Positive HER Negative Breast Cancer Preclinical Stage Products

10. HR Positive HER Negative Breast Cancer Therapeutics Assessment

11. HR Positive HER Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. HR Positive HER Negative Breast Cancer Key Companies

14. HR Positive HER Negative Breast Cancer Key Products

15. HR Positive HER Negative Breast Cancer Unmet Needs

16 . HR Positive HER Negative Breast Cancer Market Drivers and Barriers

17. HR Positive HER Negative Breast Cancer Future Perspectives and Conclusion

18. HR Positive HER Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com